Skip to content

EPS (Basic) at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$0.55-43.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$0.84+4.5%
Arrowhead Research logo
Arrowhead ResearchARWR
-$0.93-133%
United Therapeutics logo
United TherapeuticsUTHR
$6.32-12.0%
Biogen logo
BiogenBIIB
$2.17+31.5%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's EPS (basic)?
PTC Therapeutics (PTCT) reported EPS (basic) of -$0.03 in Q1 2026.
How has PTC Therapeutics's EPS (basic) changed year-over-year?
PTC Therapeutics's EPS (basic) decreased by 100.3% year-over-year, from $11.09 to -$0.03.
What is the long-term trend for PTC Therapeutics's EPS (basic)?
Over 3 years (2021 to 2024), PTC Therapeutics's EPS (basic) has grown at a -13.9% compound annual growth rate (CAGR), from -$7.42 to -$4.73.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.